Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Miller RA, Ding N, Reneau JC, Song Y, Yoon DH, Feldman TA, Yannakou CK, Kim WS, Gasiorowski R, Kim YH, Khodadoust MS, Radeski D, Giri P, Shin HJ, Yoon SS, Mehta-Shah N, Akilov OE, Khot AS, Sungala NP, Mahabhashyam S, Wilcox RA

Open source

DOI: 10.1182/blood.2026034704
Published: 2026 Aug 25
Container: Blood
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood.2026034704,
  title = {Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.},
  author = {Miller RA and Ding N and Reneau JC and Song Y and Yoon DH and Feldman TA and Yannakou CK and Kim WS and Gasiorowski R and Kim YH and Khodadoust MS and Radeski D and Giri P and Shin HJ and Yoon SS and Mehta-Shah N and Akilov OE and Khot AS and Sungala NP and Mahabhashyam S and Wilcox RA},
  year = {2026},
  journal = {Blood},
  doi = {10.1182/blood.2026034704},
  url = {https://doi.org/10.1182/blood.2026034704}
}

RIS

TY  - JOUR
TI  - Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.
AU  - Miller RA
AU  - Ding N
AU  - Reneau JC
AU  - Song Y
AU  - Yoon DH
AU  - Feldman TA
AU  - Yannakou CK
AU  - Kim WS
AU  - Gasiorowski R
AU  - Kim YH
AU  - Khodadoust MS
AU  - Radeski D
AU  - Giri P
AU  - Shin HJ
AU  - Yoon SS
AU  - Mehta-Shah N
AU  - Akilov OE
AU  - Khot AS
AU  - Sungala NP
AU  - Mahabhashyam S
AU  - Wilcox RA
PY  - 2026
JO  - Blood
DO  - 10.1182/blood.2026034704
UR  - https://doi.org/10.1182/blood.2026034704
ER  -

APA

RA, M., N, D., JC, R., Y, S., DH, Y., TA, F., CK, Y., WS, K., R, G., YH, K., MS, K., D, R., P, G., HJ, S., SS, Y., N, M., OE, A., AS, K., NP, S., S, M., & RA, W. (2026). Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.. Blood. https://doi.org/10.1182/blood.2026034704

Source records

pubmed · retrieved 2026-09-27T10:14:30.287Z